Effects of Astragaloside IV on treatment of breast cancer cells execute possibly through regulation of Nrf2 via PI3K/AKT/mTOR signaling pathway

Xiao‐Qing Zhang; Chang Yao; Wei‐He Bian; Xu Chen; Jing‐Xian Xue; Zhi‐Yuan Zhu; Yu Ying; Yan Lei Xu; Cong Wang

doi:10.1002/fsn3.1154

journal article Open Access Sep 18, 2019

Effects of Astragaloside IV on treatment of breast cancer cells execute possibly through regulation of Nrf2 via PI3K/AKT/mTOR signaling pathway

Xiao‐Qing Zhang Chang Yao

Wei‐He Bian Xu Chen

Jing‐Xian Xue Zhi‐Yuan Zhu Yu Ying Yan Lei Xu Cong Wang

Food Science & Nutrition Vol. 7 No. 11 pp. 3403-3413 · Wiley

View at Publisher Save 10.1002/fsn3.1154

Abstract

AbstractTraditional Chinese medicine (TCM) has from ancient times been applied in China for the treatment of breast cancer with its own unique theoretical system. Sanhuang decoction composed of astragalus membranaceus, prepared rhubarb, and rhizoma curcumae longae has traditionally been used for antioxidant stress, inflammatory reaction, and angiogenesis. However, the role and mechanism of Sanhuang decoction in breast cancer remains unknown. The present study demonstrated the antitumor activity of Sanhuang decoction against breast cancer xenografts in nude mice. Notably, Sanhuang decoction promoted severe necrosis and induced cell death. In addition, Sanhuang decoction obviously regulated the inflammation and oxidative stress. Despite these, Sanhuang decoction could increase the expression of Nrf2. Moreover, si‐Nrf2 exhibited the opposite effects compared with the Sanhuang decoction treatment group and reversed the antibreast cancer role of Sanhuang decoction. Further, Sanhuang decoction remarkably suppressed the expression of PI3K/AKT/mTOR signaling pathway. Taken together, Sanhuang decoction was firstly evaluated to possess potent antibreast cancer effect in vivo through regulation of inflammation and oxidative stress accomplished by up‐regulation of Nrf2 via PI3K/AKT/mTOR signaling pathway and Sanhuang decoction might be a powerful candidate formula for antibreast cancer.

Topics

No keywords indexed for this article. Browse by subject →

References

52

[1]

10.3390/ijms16023528

[2]

10.1517/14728222.2011.644788

[3]

10.1002/ijc.24106

[4]

10.1016/j.semcancer.2005.07.006

[5]

10.1016/s0092-8674(02)01083-8

[6]

10.1002/cncr.22656

[7]

10.2174/09298673113209990106

[8]

10.3322/caac.21338

[9]

Inflammation and cancer

Lisa M. Coussens, Zena Werb

Nature 10.1038/nature01322

[10]

10.1016/s0140-6736(16)31795-0

[11]

10.3322/caac.21203

[12]

10.1016/s1470-2045(14)70263-3

[13]

10.1128/mcb.05437-11

[14]

PI3K and cancer: lessons, challenges and opportunities

David A. Fruman, Christian Rommel

Nature Reviews Drug Discovery 10.1038/nrd4204

[15]

10.1186/bcr312

[16]

10.1007/978-3-319-16366-6_1

[17]

10.7314/apjcp.2012.13.12.6295

[18]

10.1158/0008-5472.can-12-1474

[19]

10.1016/j.freeradbiomed.2008.10.040

[20]

10.1016/j.urolonc.2014.02.006

[21]

10.1002/14651858.cd005212.pub3

[22]

Hsieh T. C. "Differential suppression of proliferation in MCF‐7 and MDA‐MB‐231 breast cancer cells exposed to alpha‐, gamma‐ and delta‐tocotrienols is accompanied by altered expression of oxidative stress modulatory enzymes" Anticancer Research (2010)

[23]

10.7314/apjcp.2013.14.9.5231

[24]

10.1016/j.mce.2013.06.003

[25]

10.1245/s10434-014-3859-3

[26]

10.1177/0192623309356453

[27]

10.1016/s0076-6879(04)78021-0

[28]

10.1016/j.taap.2009.08.028

[29]

10.1002/cncr.28579

[30]

10.1186/s12906-018-2204-y

[31]

10.1016/s0254-6272(17)30053-5

[32]

10.2174/09298673113209990124

[33]

10.1001/jamasurg.2013.3393

[34]

10.1007/s11655-017-2798-9

[35]

10.1073/pnas.91.21.9926

[36]

10.1016/j.chc.2014.05.011

[37]

10.1016/j.bbcan.2013.02.005

[38]

10.1016/j.soncn.2015.02.002

[39]

10.1158/0008-5472.can-13-0687

[40]

10.1155/2014/686984

[41]

Cancer statistics, 2017

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal

CA: A Cancer Journal for Clinicians 10.3322/caac.21387

[42]

10.1158/0008-5472.can-08-1401

[43]

10.1016/s0954-6111(11)70008-7

[44]

10.1016/j.fct.2017.08.010

[45]

10.1097/md.0000000000007918

[46]

10.1016/j.canlet.2008.02.044

[47]

10.3892/or.2016.4954

[48]

10.1007/s11655-013-1538-z

[49]

10.1007/s12013-014-0348-z

[50]

10.47102/annals-acadmedsg.v43n2p74

Showing 50 of 52 references

Metrics

24

Citations

52

References

Details

Published: Sep 18, 2019
Vol/Issue: 7(11)
Pages: 3403-3413
License: View

Authors

X

Xiao‐Qing Zhang